Rheumatoid Arthritis Clinical Trial
Official title:
Immune Response to Varicella Zoster Vaccination (ZOSTAVAX) in Subjects With Rheumatoid Arthritis
NCT number | NCT01506661 |
Other study ID # | OMRF11-53 |
Secondary ID | |
Status | Completed |
Phase | Phase 1 |
First received | |
Last updated | |
Start date | January 2012 |
Est. completion date | October 2018 |
Verified date | March 2020 |
Source | Oklahoma Medical Research Foundation |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Herpes Zoster (shingles) is caused by reactivation of latent varicella zoster virus (VZV)
that usually occurs decades following initial exposure. The risk of developing shingles
increases with age. Shingles presents as a painful, itchy blistering rash that usually
involves a single portion of the skin and lasts about 7-10 days. The risk of developing
shingles increases with age in healthy people, and has been shown in some studies to be
increased in people with rheumatoid arthritis and other autoimmune diseases.
Zostavax, a live-attenuated vaccine against the varicella zoster virus, was first approved by
the FDA for the prevention of Shingles among people 60 years and older, and is now approved
for use in people aged 50 years and older. Because rheumatoid arthritis and some of the
medications used to treat rheumatoid arthritis can impair the body's immune system, it is not
known how much of an immune response can be generated in people with rheumatoid arthritis.
The goals of this study are to measure the immune response after standard vaccination with
Zostavax in people with rheumatoid arthritis in comparison to people with healthy immune
systems. All participants will be 50 years old or older, and subjects with rheumatoid
arthritis will not be eligible if they are taking certain biologic medications, including TNF
inhibitors (Etanercept or Adalimumab). Ten healthy subjects and 10 subjects with rheumatoid
arthritis will all receive a single vaccination with Zostavax, then will be followed for 12
weeks to assess the immune response and for the development of local rash or other potential
side effects.
Status | Completed |
Enrollment | 20 |
Est. completion date | October 2018 |
Est. primary completion date | December 2017 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 50 Years to 80 Years |
Eligibility |
Inclusion Criteria: - Age = 50 years - Willing and able to provide written informed consent - History of primary varicella vaccination or positive VZV IgG antibodies - Diagnosis of RA according to ACR criteria for > 1 year, or healthy control subject - Stable, mild disease activity as defined by a DAS28 score of 4.0 - Current medical treatment for RA has been stable for 4 weeks prior to screening - Acceptable immunosuppressive medications are limited to Prednisone = 10 mg daily Methotrexate = 20 mg weekly Hydroxychloroquine = 6.5 mg/kg daily Any TNF inhibitor - Female subjects of childbearing potential and non-sterile males must agree to use acceptable form of contraception for the duration of the study Exclusion Criteria: - History of receiving any VZV-containing vaccine - History of herpes zoster reactivation (shingles) within 5 years of enrollment - Received any vaccine within 6 weeks - Known Hepatitis B, C or HIV virus infection - History of drug or alcohol abuse within 1 year - Rituximab therapy within 2 years of screening - Cyclophosphamide within 6 months of screening - Biologic therapy: TNF inhibitors with longer half-lives (infliximab, golimumab, etc), or other non-TNF biologic therapies (IL-1 or IL-6 inhibition, or CTLA-4Ig) - Use of mycophenolate mofetil within 3 months of screening - History of receiving immunoglobulin or other blood product within 3 months of screening - Allergic reaction, intolerance or other contraindication to use of famciclovir. - Has received an experimental/investigational agent (vaccine, drug, biologic, device, blood product, or medication) within 3 months of screening; or expects to receive another experimental/investigational agent within 6 months post immunization. - Pregnant or lactating women - Unwilling to use acceptable method of contraception for the duration of the study - WBC <3.0; ANC <1500; CD4+ <200 - Proteinuria >1.5 mg/day - Impaired renal function defined by serum Cr >1.5 - Transaminases > 2x upper limit of normal - DAS28 > 4 - Anticipation of need to increase level of immunosuppression or add biologic therapy for 6 months following dosing. - History of neoplastic disease within 5 years of screening, except for completely excised non-melanoma cancer of the skin or in-situ carcinoma of the uterine cervix. - History of any hematological malignancy, current bleeding disorder or taking anticoagulant medication (heparin or warfarin). - Any condition that would, in the opinion of the site investigator, place the subject at an unacceptable risk of injury or render the subject unable to meet the requirements of the protocol. |
Country | Name | City | State |
---|---|---|---|
United States | Oklahoma Medical Research Foundation | Oklahoma City | Oklahoma |
Lead Sponsor | Collaborator |
---|---|
Oklahoma Medical Research Foundation |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety and development of localized herpes zoster lesions | The primary outcome of the study is assessment of adverse events, including injection site reactions and development of zoster-like lesions, following vaccination in subjects with RA compared to healthy subjects | 12 weeks | |
Secondary | Immunogenicity | The secondary objective of the study is immunogenicity. Specifically, the change from baseline in varicella-zoster virus-specific cell mediated immunity (assessed by IFN-g ELISpot) between subjects with RA and healthy subjects will be compared. | 6 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04226131 -
MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics
|
N/A | |
Completed |
NCT04171414 -
A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT02833350 -
Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)
|
Phase 2 | |
Completed |
NCT04255134 -
Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN)
|
Phase 4 | |
Recruiting |
NCT05615246 -
Exactech Humeral Reconstruction Prosthesis of Shoulder Arthroplasty PMCF (HRP)
|
||
Completed |
NCT03248518 -
Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases
|
N/A | |
Completed |
NCT03514355 -
MBSR in Rheumatoid Arthritis Patients With Controlled Disease But Persistent Depressive Symptoms
|
N/A | |
Recruiting |
NCT06005220 -
SBD121, a Synbiotic Medical Food for RA Management
|
N/A | |
Recruiting |
NCT05451615 -
Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT05054920 -
Eccentric Versus Concentric Exercises for Rotator Cuff Tendinopathy in Patients With Rheumatoid Arthritis
|
N/A | |
Completed |
NCT02037737 -
Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting
|
N/A | |
Recruiting |
NCT04079374 -
Comparative Efficacy, Safety and Immunogenicity Study of Etanercept and Enbrel
|
Phase 3 | |
Completed |
NCT02504268 -
Effects of Abatacept in Patients With Early Rheumatoid Arthritis
|
Phase 3 | |
Recruiting |
NCT05496855 -
Remote Care in People With Rheumatoid Arthritis
|
N/A | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Recruiting |
NCT06103773 -
A Study of Single and Multiple Oral Doses of TollB-001
|
Phase 1 | |
Recruiting |
NCT06031415 -
Study of GS-0272 in Participants With Rheumatoid Arthritis
|
Phase 1 | |
Completed |
NCT05999266 -
The Cartilage and Muscle Thickness on Knee Pain in Patients With Rheumatoid Arthritis
|
||
Recruiting |
NCT05302934 -
Evaluation of the PHENO4U Data Platform in Patients Undergoing Total Knee Arthroplasty
|
||
Recruiting |
NCT04169100 -
Novel Form of Acquired Long QT Syndrome
|
Phase 4 |